Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration.

Park D, Shah V, Rauck BM, Friberg TR, Wang Y.

Macromol Biosci. 2013 Apr;13(4):464-9. doi: 10.1002/mabi.201200384. Epub 2013 Jan 11.

2.

Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.

Rauck BM, Friberg TR, Medina Mendez CA, Park D, Shah V, Bilonick RA, Wang Y.

Invest Ophthalmol Vis Sci. 2014 Jan 23;55(1):469-76. doi: 10.1167/iovs.13-13120.

3.

A functionalizable reverse thermal gel based on a polyurethane/PEG block copolymer.

Park D, Wu W, Wang Y.

Biomaterials. 2011 Jan;32(3):777-86. doi: 10.1016/j.biomaterials.2010.09.044.

4.

Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye.

Kang Derwent JJ, Mieler WF.

Trans Am Ophthalmol Soc. 2008;106:206-13; discussion 213-4.

5.
6.

Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.

Torjesen I.

BMJ. 2013 Jul 23;347:f4678. doi: 10.1136/bmj.f4678. No abstract available.

PMID:
23881948
7.

Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.

Hawkes N.

BMJ. 2012 Jul 30;345:e5161. doi: 10.1136/bmj.e5161. No abstract available.

PMID:
22846417
8.

Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).

Rhodes C, Harris J, Sulston J, Spanswick C.

J Med Ethics. 2012 Mar;38(3):187-9. doi: 10.1136/medethics-2011-100032. Epub 2011 Sep 24.

9.

Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.

Torjesen I.

BMJ. 2012 Apr 24;344:e2959. doi: 10.1136/bmj.e2959. No abstract available.

PMID:
22532011
10.

Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery.

Xu X, Weng Y, Xu L, Chen H.

Int J Biol Macromol. 2013 Sep;60:272-6. doi: 10.1016/j.ijbiomac.2013.05.034. Epub 2013 Jun 5.

PMID:
23748006
11.

Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.

Messori A, Fadda V, Trippoli S.

Am J Ophthalmol. 2010 May;149(5):867; author reply 867. doi: 10.1016/j.ajo.2009.12.039. No abstract available.

PMID:
20399931
12.

Bevacizumab must be specially prepared for intraocular use.

Georgalas I, Papaconstantinou D, Paraskevopoulos T, Koutsandrea C.

BMJ. 2013 Aug 14;347:f5032. doi: 10.1136/bmj.f5032. No abstract available.

PMID:
23945366
13.

Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.

Johnson D, Sharma S.

Curr Opin Ophthalmol. 2013 May;24(3):205-12. doi: 10.1097/ICU.0b013e32835f8ec0. Review.

PMID:
23518613
14.

Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin(®) ) in neovascular age-related macular degeneration.

Bonnin P, Pournaras JA, Lazrak Z, Cohen SY, Legargasson JF, Gaudric A, Levy BI, Massin P.

Acta Ophthalmol. 2010 Sep;88(6):641-5. doi: 10.1111/j.1755-3768.2009.01526.x.

15.

Ranibizumab for age-related macular degeneration.

Cheng JW, Wei RL.

N Engl J Med. 2011 Feb 10;364(6):582. doi: 10.1056/NEJMc1013316#SA2. No abstract available.

PMID:
21306263
16.

Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.

Schachat AP.

Am J Ophthalmol. 2013 Jul;156(1):1-2.e1. doi: 10.1016/j.ajo.2013.04.009. No abstract available.

PMID:
23791369
17.

Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.

Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, Geyer O.

Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1435-40. doi: 10.1007/s00417-012-1981-0. Epub 2012 Mar 21.

PMID:
22434210
18.

On further development of barrier modulation as a technique for systemic ocular drug delivery.

Hanrahan F, Campbell M, Nguyen AT, Suzuki M, Kiang AS, Tam LC, Gobbo OL, Dhubhghaill SN, Humphries MM, Kenna PF, Humphries P.

Adv Exp Med Biol. 2012;723:155-9. doi: 10.1007/978-1-4614-0631-0_21. Review. No abstract available.

PMID:
22183328
19.

Effects of repeated intravitreal bevacizumab injections on the inner retinal function in neovascular age-related macular degeneration.

Kim HD, Kim SH, Cho IH, Moon CH, Ohn YH, Park TK.

Acta Ophthalmol. 2013 Mar;91(2):e154-6. doi: 10.1111/j.1755-3768.2012.02546.x. Epub 2012 Sep 19. No abstract available.

20.

Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.

Axer-Siegel R, Bor E, Bourla DH, Weinberger D, Mimouni K.

Retina. 2012 Oct;32(9):1811-20.

PMID:
22825407
Items per page

Supplemental Content

Write to the Help Desk